Latest News
& Press Releases
Browse the latest news from BioSpace, and press releases from around the industry. Want to filter by date, keyword, and more? Search here.
TOP STORIES
With the holidays around the corner and people expected to gather, public health officials have expressed concerns over a possible increase in COVID-19 cases, particularly with the highly infectious Omicron variant on the rise.
U.S. District Judge Colleen McMahon rejected a bankruptcy plan that shielded the Sackler family from potential lawsuits related to the opioid crisis.
In a unanimous vote made by U.S. health officials, the advisers decided the safer Pfizer and Moderna vaccines should be given as boosters.
BeiGene and other China-based pharma companies have been nervously watching the Biden administration and its response to some companies in that region that have allegedly been involved with the Chinese military’s weapons programs and human rights violations.
The avalanche of news released every day about all three - or various combinations thereof - can be overwhelming. So, BioSpace has put together a chart for easy comparative reference.
It is also a milestone for the immunoglobulin A nephropathy (IgAN) community, as TARPEYO becomes the first and only FDA-approved treatment to reduce proteinuria in this condition.
As 2021 moves closer to its end, biopharma and life sciences companies from across the globe continue to strengthen their leadership teams and boards with these Movers & Shakers.
The new funding will allow the biotech company to advance its programs and accelerate the development of life-saving treatments for neurodegenerative diseases.
The agreement between the two companies includes a lead, potential first-in-class preclinical candidate, and research collaboration to jointly develop the additional novel candidates.
A recent study estimates that in the U.S. alone the vaccines saved 1.1 million lives and prevented 10.3 million hospitalizations. For that and more COVID-19 news, continue reading.
Arc begins its mission with $650 million in donations from donors. This funding will sustain the scientists and their researchers over renewable eight-year terms.
A recent study identified a hormone that may drive both type 1 and type 2 diabetes. For that and more research stories, read on.
PRESS RELEASES
New START site to be established in collaboration with Baptist Health Herbert Wertheim Cancer Institute will bring novel oncology therapies closer to patients across South Florida
• Augurex’s SPINEstat® (Anti-14-3-3eta Multiplex for axial spondyloarthritis) test has been selected as a finalist in the ADLM 2026 Disruptive Technology Award, one of laboratory medicine’s most competitive recognition programs. • Augurex will present at ADLM 2026 on July 27 in Anaheim, CA, with a dedicated finalist kiosk on the Expo Floor July 28–30. • The recognition underscores Augurex’s leadership in developing biomarker-driven diagnostics that address critical unmet needs across autoimmune and inflammatory diseases.
